1069P - Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

D.O Jackson,K.M Peace,D.F Hale,T.J Vreeland,G Choy,B Nejadnik,J.M Greene,E.J Schneble,J.S Berry,A.F Trappey,M.O Hardin,G.T Clifton,G.S Herbert,E Mittendorf,J.P Holmes,G.E Peoples

doi:10.1093/annonc/mdw378.23

1069P - Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

D.O Jackson, K.M Peace + Show 14 more

Open Access

https://doi.org/10.1093/annonc/mdw378.23

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2016
License type: elsevier-specific: oa user license

Affiliation: Galena Biopharma (United States), The University of Texas MD Anderson Cancer Center, Pharmaceutical Product Development (United States)

#HER2 Low Expression #Prevent Breast Cancer Recurrence + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1069P - Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

Full Text